New Delhi, February 5, 2025 – Poly Medicure Limited (BSE: 531768, NSE: POLYMED) has reported its unaudited standalone and consolidated financial results for the third quarter (Q3) and nine months ended December 31, 2024, for the financial year 2024-25 (FY25). The company posted strong revenue growth and profitability, driven by robust operational performance and strategic initiatives.
Key Financial Highlights (Standalone and Consolidated) for Q3 & 9M FY25
Standalone Performance
| Particulars | Q3 FY25 (₹ in lakhs) | Q2 FY25 (₹ in lakhs) | Q3 FY24 (₹ in lakhs) | 9M FY25 (₹ in lakhs) | 9M FY24 (₹ in lakhs) |
|---|---|---|---|---|---|
| Revenue from Operations | 41,093.71 | 40,246.86 | 32,086.35 | 118,083.64 | 94,632.06 |
| Total Income | 43,268.49 | 42,971.31 | 33,742.84 | 124,665.42 | 98,883.83 |
| EBITDA | 11,338.99 | 11,692.95 | 8,208.97 | 32,639.47 | 24,092.16 |
| Profit Before Tax (PBT) | 11,338.99 | 11,692.95 | 8,208.97 | 32,639.47 | 24,092.16 |
| Net Profit | 8,515.16 | 8,722.04 | 6,146.08 | 24,316.70 | 18,034.69 |
| Earnings Per Share (EPS) - Basic (₹) | 8.48 | 8.99 | 6.41 | 25.00 | 18.89 |
Consolidated Performance
| Particulars | Q3 FY25 (₹ in lakhs) | Q2 FY25 (₹ in lakhs) | Q3 FY24 (₹ in lakhs) | 9M FY25 (₹ in lakhs) | 9M FY24 (₹ in lakhs) |
|---|---|---|---|---|---|
| Revenue from Operations | 42,421.19 | 42,001.51 | 33,959.82 | 122,900.62 | 99,775.21 |
| Total Income | 44,601.28 | 44,611.32 | 35,616.58 | 129,382.15 | 104,149.72 |
| EBITDA | 11,322.63 | 11,798.21 | 8,782.46 | 33,966.58 | 25,181.23 |
| Profit Before Tax (PBT) | 11,322.63 | 11,798.21 | 8,782.46 | 33,966.58 | 25,181.23 |
| Net Profit | 8,172.02 | 8,753.56 | 6,501.59 | 24,672.29 | 18,990.18 |
| Earnings Per Share (EPS) - Basic (₹) | 8.48 | 9.01 | 6.78 | 25.21 | 19.79 |
Segment-Wise Performance
Poly Medicure operates primarily in the medical devices sector, which remains its sole reportable segment as per Ind AS 108. The company has experienced strong growth in domestic and international markets, with significant contributions from its subsidiaries.Corporate Announcements
- Equity Shares Allotment under ESOP 2020
- 35,150 equity shares were allotted at ₹100 per share under the Employee Stock Option Scheme (ESOP) 2020 during Q3 FY25.
- Qualified Institutional Placement (QIP) Issue
- The company successfully raised ₹99,999.98 lakhs through QIP in August 2024, issuing 53,19,148 equity shares at ₹1,880 per share.
- Utilization of QIP Proceeds:
- ₹1,460.50 lakhs for QIP-related expenses
- ₹8,499.98 lakhs for repayment of working capital limits
- ₹90,039.50 lakhs temporarily invested in liquid mutual funds pending utilization.
- Expansion and Investment
- The company continues to invest in capacity expansion and research & development to enhance its product portfolio and global footprint.
Management Commentary
Himanshu Baid, Managing Director of Poly Medicure Limited, stated:"We have achieved consistent growth in revenue and profitability due to our strong operational execution, product innovation, and global expansion. The successful completion of our QIP has further strengthened our balance sheet, enabling us to pursue new opportunities in the medical devices sector. We remain optimistic about the future, with a strong pipeline of new product launches and strategic investments."
Strategic Outlook
- Robust Demand for Medical Devices: The increasing demand for high-quality medical devices globally positions Poly Medicure for sustained growth.
- Expansion Plans: The company plans to enhance production capacity and strengthen its presence in international markets, including Europe and the US.
- Innovation and R&D: Continuous investment in research and technology will drive long-term growth.